ArticleBMJ open2026
Developing an individualised prostate biopsy algorithm in patients with PI-RADS ≥3 lesions: a prospective multicentre cohort study protocol in China.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate biopsy remains the gold standard for prostate cancer diagnosis. Current guidelines recommend combining MRI-targeted biopsy with systematic biopsy (SB) to maximise detection of clinically significant prostate cancer (csPCa), but high-level evidence for individualised strategies remains limited, particularly for Prostate Imaging-Reporting and Data System (PI-RADS) ≥3 lesions. This study aims to determine the optimal biopsy approach for these patients. METHODS AND ANALYSIS: This prospective, multicentre cohort study will enrol 300 treatment-naive patients with PI-RADS ≥3 lesions across six centres. Patients with PI-RADS=3 will choose between active surveillance (total prostate-specific antigen and multiparametric MRI monitoring) or immediate 12-core SB. Patients with PI-RADS ≥4 will undergo combined biopsy with comparison of 12-core, 6-core and targeted-only strategies. The primary endpoint is csPCa detection rate (International Society of Urological Pathology grade ≥2). Secondary endpoints include any prostate cancer detection, false-negative rates and complications. Analysis includes non-inferiority testing, logistic regression and receiver operating characteristic curve analysis. ETHICS AND DISSEMINATION: The study has been approved by the institutional review board at Shenzhen Hospital of Southern Medical University (No. NYSZYYEC2025K150R001) with local approval at each site. All participants will provide written informed consent. Results will be submitted to peer-reviewed journals and presented at international urology conferences. TRIAL REGISTRATION NUMBER: ChiCTR2500114101.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.